# The specificity of HEG1 as mesothelioma marker depends on the differential diagnosis

**Authors:** Ben Davidson, Lara Maria Stričak, Arild Holth, Annette Torgunrud, Jeremias Wohlschlaeger, Martin Tötsch, Assia Bassarova

PMC · DOI: 10.1007/s00428-026-04438-w · Virchows Archiv · 2026-02-09

## TL;DR

This study shows that HEG1 is a sensitive marker for mesothelioma but its usefulness depends on the type of cancer being compared.

## Contribution

The study reveals HEG1's variable specificity in distinguishing mesothelioma from different carcinomas.

## Key findings

- HEG1 is highly sensitive for mesothelioma but has low specificity against tubo-ovarian carcinoma.
- HEG1 is frequently expressed in tubo-ovarian carcinoma effusions and surgical specimens.
- HEG1 is consistently expressed in reactive mesothelial and endothelial cells.

## Abstract

The objective of this study was to analyze the diagnostic role of HEG homolog 1 (HEG1) in cancers affecting the serosal cavities. HEG1 protein expression by immunohistochemistry was analyzed in 534 specimens (341 effusions and 193 surgical specimens). Effusions consisted of 151 tubo-ovarian carcinomas, 59 breast carcinomas, 44 mesotheliomas, 37 lung carcinomas, 29 uterine corpus and cervical carcinomas, 17 gastrointestinal carcinomas and 4 genitourinary carcinomas. Surgical specimens consisted of 139 tubo-ovarian carcinomas, 42 mesotheliomas, 7 multicystic mesothelial proliferations and 5 papillary mesothelial tumors. HEG1 expression was found in 43/44 (98%) mesothelioma effusions and 39/42 (93%) surgical mesothelioma specimens, as well as all multicystic and papillary mesothelial tumors. HEG1 was infrequently expressed in breast carcinoma (4/59; 7%), lung carcinoma (2/37; 5%) and cervical/uterine carcinoma effusions (3/29; 10%), but was often detected in tubo-ovarian carcinoma effusions (80/151; 53%) and surgical specimens (99/139, 71%). HEG1 was additionally consistently expressed by reactive mesothelial cells in effusions and in endothelial cells in surgical specimens. HEG1 had sensitivity of 95% for diagnosing malignant mesothelioma in all studied specimens, with a specificity of 38% in the differential diagnosis from tubo-ovarian carcinoma and 93% in the differential diagnosis from non-tubo-ovarian carcinomas. Of 179 HEG1-positive carcinomas, 172 expressed the epithelial marker claudin-4. In conclusion, HEG1 is a highly sensitive marker of both benign and malignant mesothelial cells. It shows high specificity in the differentiation of mesothelioma from lung or breast carcinoma but is of little value in differentiating mesothelioma from tubo-ovarian carcinoma. The potential role of HEG1 as vascular marker merits further research.

## Linked entities

- **Genes:** HEG1 (heart development protein with EGF like domains 1) [NCBI Gene 57493]
- **Proteins:** HEG1 (heart development protein with EGF like domains 1), Claudin-4 (claudin-4)
- **Diseases:** mesothelioma (MONDO:0005065), breast carcinoma (MONDO:0004989), lung carcinoma (MONDO:0005138), gastrointestinal carcinoma (MONDO:0006181)

## Full-text entities

- **Genes:** CLDN4 (claudin 4) [NCBI Gene 1364] {aka CPE-R, CPER, CPETR, CPETR1, WBSCR8, hCPE-R}, HEG1 (heart development protein with EGF like domains 1) [NCBI Gene 57493] {aka HEG, MST112, MSTP112}
- **Diseases:** cervical/uterine carcinoma (MESH:D002583), gastrointestinal carcinomas (MESH:D005770), breast carcinoma (MESH:D001943), mesothelioma (MESH:D008654), genitourinary carcinomas (MESH:D014565), lung carcinoma (MESH:D008175), non-tubo-ovarian carcinomas (MESH:D010051), cancers (MESH:D009369), and papillary mesothelial tumors (MESH:D018301), malignant mesothelioma (MESH:D000086002)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12963136/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12963136/full.md

---
Source: https://tomesphere.com/paper/PMC12963136